Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation and Depletion (2016 - 2017)

Historic Depreciation and Depletion for Intellia Therapeutics (NTLA) over the last 3 years, with Q1 2017 value amounting to $660000.0.

  • Intellia Therapeutics' Depreciation and Depletion rose 25294.12% to $660000.0 in Q1 2017 from the same period last year, while for Mar 2017 it was $1.6 million, marking a year-over-year increase of 24647.58%. This contributed to the annual value of $3.0 million for FY2017, which is 17272.73% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Depreciation and Depletion of $660000.0 as of Q1 2017, which was up 25294.12% from $401000.0 recorded in Q4 2016.
  • Over the past 5 years, Intellia Therapeutics' Depreciation and Depletion peaked at $660000.0 during Q1 2017, and registered a low of $33000.0 during Q1 2015.
  • Over the past 3 years, Intellia Therapeutics' median Depreciation and Depletion value was $187000.0 (recorded in 2016), while the average stood at $228888.9.
  • Within the past 5 years, the most significant YoY rise in Intellia Therapeutics' Depreciation and Depletion was 46666.67% (2016), while the steepest drop was 17604.17% (2016).
  • Intellia Therapeutics' Depreciation and Depletion (Quarter) stood at $104000.0 in 2015, then soared by 285.58% to $401000.0 in 2016, then skyrocketed by 64.59% to $660000.0 in 2017.
  • Its Depreciation and Depletion was $660000.0 in Q1 2017, compared to $401000.0 in Q4 2016 and $265000.0 in Q3 2016.